• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

CNS Summit 2017 Abstracts of Poster Presentations
Conclusion: This novel technology discriminates and quantifies subtle differences in behavior and neurological impairments in subjects afflicted with neurological injury/disease. KINARM assessments can be incorporated into multi-center trials (e.g., monitoring stroke motor recovery: NCT02928393). Further studies will determine if KINARM Labs can demonstrate a clinical effect with fewer subjects over a shorter trial period. Disclosures/funding: Dr. Stephen Scott is the inventor of KINARM and CSO of BKIN Technologies.   Multiplexed mass spectrometry assay identifies neurodegeneration biomarkers in CSF Presenter: Chelsky...
Source: Innovations in Clinical Neuroscience - November 1, 2017 Category: Neuroscience Authors: ICNS Online Editor Tags: Assessment Tools biomarkers Cognition Current Issue Drug Development General Genetics Medical Issues Neurology Patient Assessment Psychopharmacology Scales Special Issues Supplements Trial Methodology clinical trials CNS Su Source Type: research

Treatment Of Panx1-Related Diseases Could Involve Food Dye
The food dye Brilliant Blue FCF (BB FCF) could be a useful tool in the development of treatments for a variety of conditions involving the membrane channel protein Pannexin 1(Panx1), according to a study in The Journal of General Physiology. Panx1, which is involved in signaling events leading to inflammation and cell death, has been implicated in such diverse diseases as Crohn's, AIDS, melanoma, epilepsy, spinal cord injury, and stroke, among others. Thus, there is a demand for the development of pharmacological tools to inhibit Panx1...
Source: Health News from Medical News Today - May 1, 2013 Category: Consumer Health News Tags: Immune System / Vaccines Source Type: news